Pigment Disorders: Lightening Melasma and Repigmenting Vitiligo

One factory, one master switch

Every pigment story begins and ends at tyrosinase. Skin colour is manufactured in melanocytes, dendritic cells that sit along the base of the epidermis and hand off packets of pigment (melanosomes) to the surrounding keratinocytes like a baker passing loaves over a counter. Inside the melanosome, the pigment melanin is built from the amino acid tyrosine along an assembly line whose slowest, rate-limiting step is run by a single copper-dependent enzyme: tyrosinase. Because tyrosinase gates the whole pathway, it is the master switch of pigmentation — and, conveniently, the single most drug-able target in the entire system. Almost every skin-lightening agent works, directly or indirectly, by turning tyrosinase down. Ultraviolet light does the opposite: it revs the melanocyte and drives melanin up, which is exactly why the sun is the pigment story's recurring villain.

Too much pigment: melasma and post-inflammatory hyperpigmentation

Two everyday problems overproduce melanin. Melasma is a symmetrical, blotchy brown patterning of the face driven by a trio: female sex hormones (it flares in pregnancy and on the pill), genetics, and above all ultraviolet and even visible light. Post-inflammatory hyperpigmentation (PIH) is the brown stain left behind after acne, eczema or any injury — the melanocyte's overzealous response to inflammation, most stubborn in darker skin. Both share the same therapeutic goal: dial melanin down. And both share the same non-negotiable foundation, discussed at the end — without disciplined sun protection, every lightening drug is bailing water out of a boat with the tap still running.

Hydroquinone and the triple combination

For half a century, one molecule has been the gold standard of skin lightening. Hydroquinone is the reference lightening agent. It works by competitively inhibiting tyrosinase, starving the melanin assembly line of its rate-limiting step, and it is genuinely effective. Its problems are dose- and time-related. It commonly causes irritation and a transient redness. Its feared complication, with prolonged high-concentration use (especially the unregulated high-strength creams sold in some markets), is exogenous ochronosis — a paradoxical blue-black darkening of the treated skin that is far harder to reverse than the melasma it was meant to fix. For that reason hydroquinone is used in defined courses, not indefinitely, and rests are built in. The most effective prescription formulation pairs it in a triple combination — hydroquinone plus a retinoid (tretinoin) plus a mild topical corticosteroid. Each partner does a distinct job: tretinoin speeds keratinocyte turnover and helps disperse pigment (and improves hydroquinone penetration), while the low-potency steroid calms the irritation the other two provoke and dampens melanocyte activity. The three together outperform any of them alone.

Beyond hydroquinone: the alternatives

Concern about long-term hydroquinone has driven a whole shelf of alternatives, most of which also converge on tyrosinase. Azelaic acid inhibits tyrosinase and is a favourite in PIH and acne-related pigmentation because it doubles as an anti-acne and anti-inflammatory agent (it reappears in the Acne and Rosacea chapters). Kojic acid, a fungal-derived tyrosinase inhibitor, is common in cosmeceutical blends. Cysteamine, an antioxidant naturally present in cells, is a newer non-hydroquinone cream that lowers melanin through several routes and is being used for longer-term maintenance. Topical retinoids (tretinoin, and gentler adapalene) help on their own by accelerating epidermal turnover and dispersing pigment, though they can transiently irritate and, paradoxically, provoke PIH if pushed too hard in darker skin. Vitamin C (ascorbic acid) and niacinamide are milder adjuncts — the former interferes with melanin synthesis as an antioxidant, the latter blocks the transfer of finished melanosomes to keratinocytes, a different point on the same assembly line.

Oral tranexamic acid: an unexpected melasma tool

One of the most useful recent additions to stubborn melasma is a drug borrowed from an entirely different specialty. Tranexamic acid is best known as an antifibrinolytic — it stops bleeding by blocking plasmin, and in that role it appears in the Haematology chapter for menorrhagia and surgical blood loss. In melasma it is used at low oral doses for a completely different effect: it dampens the melanocyte's response to ultraviolet light, partly by interfering with the plasmin-driven signalling and the vascular/inflammatory drive that feeds melanogenesis. In practice it reduces both the pigment and the subtle redness that often underlies melasma. It is not first-line — clinicians screen for clotting risk, since anything touching the fibrinolytic system warrants caution about thrombosis — but for resistant, relapsing melasma it can be genuinely effective. It is a lovely example of the same molecule wearing two entirely different pharmacological hats depending on the dose and the target tissue.

Too little pigment: vitiligo as an autoimmune attack

In vitiligo the factory isn't broken — it is being destroyed. Vitiligo is the opposite disease: the sharply demarcated, chalk-white patches appear because the melanocytes in that skin have been destroyed. It is now firmly understood as an autoimmune disorder in which cytotoxic T cells target and kill melanocytes. The engine of the attack is a specific signalling loop: interferon-gamma (IFN-γ) released by T cells triggers keratinocytes to secrete the chemokine CXCL10, which recruits still more melanocyte-killing T cells into the skin — a self-reinforcing circuit that keeps the disease spreading. Crucially, that IFN-γ signal is relayed inside cells through the JAK–STAT pathway. Naming that loop was the breakthrough, because every rung of it is a drug target. The therapeutic aim therefore has two halves: halt the immune attack, and coax surviving melanocytes (mostly those sheltered in the hair follicle) to migrate out and repopulate the white skin with colour. Both halves take months, and patience is part of the prescription.

Calming the attack: steroids and calcineurin inhibitors

For limited, localized vitiligo the first moves are the same immunosuppressants used across inflammatory dermatology. Topical corticosteroids suppress the local T-cell attack and, on the trunk and limbs, can arrest spread and even coax some repigmentation — but they cannot be used continuously on the face or in skin folds because of atrophy, telangiectasia and steroid-induced changes, exactly as covered in the Topical Corticosteroids section. That is why the topical calcineurin inhibitors — tacrolimus ointment and pimecrolimus cream — became so important here. By blocking calcineurin they shut down T-cell activation and cytokine release without any risk of skin thinning, which makes them the preferred choice precisely where steroids are dangerous: the eyelids, face and neck. Tacrolimus is a workhorse for facial vitiligo, and its steroid-sparing mechanism links directly to the Eczema chapter, where it plays the identical role on inflamed skin. Both classes work best on recently depigmented skin and on sites rich in hair follicles, the reservoir of repigmentation.

The breakthrough: ruxolitinib cream and the JAK inhibitors

For the first time, a drug is approved not to hide vitiligo but to reverse it. The transformative advance is topical ruxolitinib, a cream that inhibits JAK1 and JAK2 — the very kinases that relay the IFN-γ signal driving the attack. Block JAK, and the IFN-γ/CXCL10 loop that recruits melanocyte-killing T cells falls silent; the siege lifts, and melanocytes begin to creep back from the follicles. Ruxolitinib cream is the first drug ever approved by the FDA specifically for the repigmentation of vitiligo — a landmark, because for decades treatment could only aim to stabilize, never to license a return of colour. Its mechanism ties directly into the broader JAK-STAT / IFN-γ theme that now runs through dermatology: the same pathway logic underlies the oral and topical JAK inhibitors and tapinarof discussed in the Eczema and Alopecia chapters, where blocking this signalling regrows hair and calms atopic skin. Repigmentation with ruxolitinib is gradual — meaningful response over months, best on the face — and, like all these agents, it works better in tandem with light.

Phototherapy and the emerging oral JAK inhibitors

The second half of vitiligo treatment is switching the factory back on, and the classic tool is narrowband ultraviolet B (NB-UVB) phototherapy. Delivered two or three times a week in a light cabinet, NB-UVB does two things at once: it locally suppresses the autoimmune attack and it directly stimulates the surviving follicular melanocytes to proliferate, migrate and pigment the white skin. It is the mainstay for widespread disease and pairs powerfully with the topical drugs — the immunosuppressant calms the attack while the light drives the regrowth. This is the one place the sun's melanocyte-stimulating power is harnessed on purpose rather than feared. For extensive or fast-moving disease, oral JAK inhibitors are the emerging frontier: taking the same IFN-γ/JAK blockade systemically, they can halt rapidly spreading vitiligo across the whole body, and combined with phototherapy they are reshaping expectations for severe cases. As with their use in Alopecia, the systemic route brings systemic monitoring — the trade-off for treating the whole skin surface at once.

Repigmentation is a marathon, not a sprint — and the burden is not only skin-deep. Whatever the regimen, patients must be counselled honestly about timelines. Melanocytes migrate slowly out of the follicles, so meaningful repigmentation takes many months, tends to start as tiny freckles of colour around hair follicles within a patch, and is fastest on the face and slowest on the hands and feet — the fingertips and lips may never fully recover. Vitiligo also carries a heavy psychosocial burden, especially in darker or more visibly affected skin, where the contrast is stark and the disease is often stigmatized; the distress is real and part of what you are treating. Setting realistic expectations, combining therapies, and supporting the patient through slow progress is as much the art of pigment medicine as choosing the molecule.

The one drug both patients share: sunscreen

Return to the two patients in the waiting room, because the same prescription tops both their lists. For the woman with melasma, ultraviolet and visible light are the engine of her disease; every unprotected day undoes weeks of lightening, and studies show melasma reliably relapses without disciplined daily photoprotection — a broad-spectrum, high-SPF, ideally tinted sunscreen that also blocks visible light is not optional, it is the foundation the drugs are built on. For the man with vitiligo, sunscreen does double duty: the depigmented patches have lost their natural melanin shield and burn easily, so they need protection from ultraviolet damage; and by keeping the surrounding normal skin from tanning, sunscreen reduces the stark contrast that makes the white patches so conspicuous. The same bottle that lightens one patient protects the other — a fitting symmetry for a subject built entirely on the two directions a single cell can be pushed. Photoprotection also connects to the Skin cancer chapter, where sunscreens are taught as primary prevention rather than cosmesis.